Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,051 recruiting studies in this area right now.
By phase
- Not applicable2,997
- Phase 21,057
- Phase 1792
- Phase 1/Phase 2437
- Phase 3436
- Phase 4234
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma327
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis132
- Type 1 Diabetes130
- Atopic Dermatitis125
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia95
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Diabetes Mellitus, Type 163
- Hodgkin Lymphoma63
- Leukemia63
- Mantle Cell Lymphoma62
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic49
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California496
- Maryland200
- Alabama178
- Florida149
- Arizona147
- Massachusetts116
- New York116
- Texas112
- Illinois83
- Colorado82
Recruiting studies6,051 total
- NCT04533217Recruiting
Vertebroplasty for multiple myeloma back pain
This trial tests whether adding a procedure called vertebroplasty to usual care can better reduce back pain from multiple myeloma. It’s for people who have a small number of spine fractures in a specific area and significant pain.
Middelfart, Region SyddanmarkAges 18 years+ - NCT06713512Recruiting
Estrogen and its effect on lung tissue in obstructive lung disease
This study looks at how the hormone estrogen affects the lungs of people with asthma or COPD. It will help researchers understand why these diseases may be different in women.
LondonAges 18–99 - NCT06302062RecruitingPhase 1
Using lymph node T cells for advanced solid tumors
This trial tests a new treatment using T cells taken from your lymph nodes to fight advanced solid tumors that have not responded to standard therapies. The goal is to see if this approach can help shrink tumors or slow their growth.
Guangzhou, GaungdongAges 18–75 - NCT06461741Recruiting
EMG biofeedback training for balance in MS
This study tests whether a special training method that uses muscle signals (called EMG biofeedback) can help people with MS improve their walking and balance. If you have problems with walking or balance and your MS is stable, you may be able to join.
Hamilton, OntarioAges 18–80 - NCT06534463Recruiting
MZL patient registry study
This study is a registry that collects information on Chinese patients with marginal zone lymphoma. It helps doctors learn more about how MZL behaves and how it is treated.
Shanghai, Shanghai MunicipalityAges 14 years+ - NCT06713187Recruiting
Interleukin-23 study in lupus and lung disease
This trial looks at a protein called interleukin-23 in people with lupus, especially those who also have lung inflammation (interstitial lung disease). The goal is to understand more about this protein's role and possibly find new ways to help.
SohagAges 18–60 - NCT06714149Recruiting
How nitrogen pollution affects pollen allergies
This study looks at how pollution from nitrogen in the environment affects pollen allergies in Belgium. It may help explain why your allergy symptoms change depending on where you live.
Leuven, Vlaams-BrabantAges 18 years+ - NCT06392906RecruitingPhase 3
Radiation for Graves' Eye Disease: 1 vs 2 Weeks
This trial tests if a shorter course of radiation (1 week) works as well as a standard longer course (2 weeks) for treating active thyroid eye disease that did not improve enough with steroid medicine. It may be an option if you still have eye symptoms after steroid treatment.
Bangkok NoiAges 18–70 - NCT02306005Recruiting
Study insulin effects on blood fats in new type 1 diabetes
This study looks at how starting insulin soon after type 1 diabetes begins affects the body’s “blood fats” (lipoproteins). It may help researchers understand whether insulin changes these levels in early disease.
PoznanAges 18–35 - NCT07598396RecruitingPhase 2
Mosunetuzumab for systemic lupus erythematosus treatment
This study tests a new drug called mosunetuzumab in people with systemic lupus erythematosus (SLE), a disease where the immune system attacks the body's own tissues. The drug is designed to help control the immune response and reduce lupus symptoms, including kidney involvement if present.
Salvador, Estado de BahiaAges 18 years+ - NCT07596784RecruitingPhase 3
Ravulizumab for Generalized Myasthenia Gravis in Chinese Adults
This trial tests whether ravulizumab, a medication that blocks part of the immune system, can improve muscle weakness and fatigue in people with generalized myasthenia gravis (gMG). The study focuses on Chinese adults who have moderate-to-severe MG symptoms despite current treatments.
BeijingAges 18–130 - NCT07600788RecruitingPhase 1
Liver Function and Safety Study of AHB-137 Injection
This study tests how a new investigational drug called AHB-137 moves through your body and affects safety in people with mild-to-moderate liver problems compared to people with normal liver function. The goal is to understand if the drug works safely in people whose livers don't work as well as they should.
Chongqing, Chongqing MunicipalityAges 18–65 - NCT07599982Recruiting
Safety test of MODI insulin adjustment system for adults
This trial tests MODI, a smartphone app that helps automatically adjust your insulin doses based on blood sugar readings from a continuous glucose monitor. The study checks if this system is safe and helps people with type 1 or type 2 diabetes manage their blood sugar better.
Baltimore, MarylandAges 18–80 - NCT07602088Recruiting
Real-world Study of Two Cancer Drugs for Chronic Lymphocytic Leukemia
This study follows patients with chronic lymphocytic leukemia (CLL)—a blood cancer—who are starting treatment with two drugs called ibrutinib and venetoclax together for a set period of time. Researchers want to understand how well this treatment works and how it affects patients' daily lives in real-world settings, rather than in a controlled lab environment.
BucharestAges 18 years+ - NCT07596901RecruitingPhase 1/Phase 2
Testing Aritinercept for Generalized Myasthenia Gravis
This study tests a new drug called aritinercept to see if it can help people with generalized myasthenia gravis (a condition where muscles weaken over time). Researchers believe this drug may reduce the immune system activity that causes muscle weakness.
Pasadena, CaliforniaAges 18–85 - NCT07597200RecruitingPhase 1
Cizutamig treatment for active thyroid eye disease
This study tests a new drug called cizutamig for thyroid eye disease (TED), a condition where the eye muscles and tissues swell due to Graves' disease. The drug is designed to reduce inflammation and may help improve symptoms like eye bulging, double vision, and discomfort.
Hefei, AnhuiAges 18–75 - NCT07598383RecruitingPhase 2
Gel treatment for mild-to-moderate atopic dermatitis
This study tests a new gel called VC005 to see if it safely reduces itching, redness, and irritation in people with atopic dermatitis (a chronic skin condition). You'll be randomly assigned to either the new gel or a placebo (inactive gel) and apply it to affected areas over several weeks.
Hangzhou, ZhejiangAges 18 years+ - NCT07598422Recruiting
Safety and Effectiveness of Canakinumab for Schnitzler's Syndrome
This study tracks how well and safely canakinumab (a medication that reduces inflammation) works in patients newly diagnosed with Schnitzler's syndrome. Schnitzler's syndrome is a rare condition causing recurring fevers, rashes, and joint pain, and this study helps doctors understand how this drug performs in real-world use.
Kobe, HyōgoAges birth+ - NCT07598448Recruiting
Study of Iptacopan Treatment for C3G Patients in Spain
This study tracks adults with C3G (a rare kidney disease where the immune system damages the filtering units) who have already received iptacopan (a new medicine) through an early access program in Spain. Researchers want to understand how well this treatment works and its safety in real-world patients.
CórdobaAges 18–100 - NCT07595653Recruiting
Efgartigimod Treatment Experience in Generalized Myasthenia Gravis
This study follows people with generalized myasthenia gravis (a condition causing muscle weakness) who are already starting a medicine called efgartigimod as part of their regular care. Researchers want to understand how this treatment affects your daily life and overall experience with the disease.
Acquaviva delle FontiAges 18 years+ - NCT07595367RecruitingPhase 2
BBD-1 immune therapy for IgA vasculitis
This trial tests a new drug called BBD-1 that may help treat IgA vasculitis, a condition where your immune system attacks small blood vessels, causing a purple rash and organ damage. The study measures how well BBD-1 reduces symptoms and side effects.
Baltimore, MarylandAges Any age - NCT07603479RecruitingPhase 1
Testing JL19001 for Advanced Cancers and Lymphoma
This is an early-stage study testing a new drug called JL19001, alone or combined with standard treatments, for people with advanced solid tumors (like melanoma, lung cancer, or kidney cancer) or relapsed/refractory B-cell lymphoma who have exhausted standard options. The trial aims to find the safest dose and understand how well the drug works.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07599813RecruitingPhase 2
Testing camoteskimab for moderate-to-severe eczema
This study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to creams alone. The drug works by targeting a protein in the body that causes eczema symptoms like itching and inflammation.
Birmingham, AlabamaAges 18–65 - NCT06715215Recruiting
Blood test study for immune thrombocytopenia
This trial looks at whether certain proteins in the blood can help doctors diagnose immune thrombocytopenia (ITP), a condition where your immune system destroys platelets. It may help find a faster, simpler way to confirm ITP.
Sohag, SahagAges 1–50
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,051 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,083 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.